share_log

Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

Morgan Stanley Maintains Underweight on Evofem Biosciences, Lowers Price Target to $0.75

摩根士丹利维持对Evofem Biosciences的减持,将目标股价下调至0.75美元
Benzinga Real-time News ·  2022/07/15 10:28

Morgan Stanley analyst Jeffrey Hung maintains Evofem Biosciences (NASDAQ:EVFM) with a Underweight and lowers the price target from $2 to $0.75.

摩根士丹利分析师洪杰弗里维持Evofem Biosciences(纳斯达克股票代码:EVFM)的减持,并将目标股价从2美元下调至0.75美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发